Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02570984 · ClinicalTrials.gov registry record · Phase 2

Preventing Asthma in High Risk Kids

A Phase 2 study of Asthma, sponsored by Boston Children's Hospital.

Active
Registry status
Phase 2
Development phase
200
Enrollment target
13
Study locations

NCT02570984: Active Phase 2 study of Asthma, sponsored by Boston Children's Hospital.

NCT02570984 is a Phase 2 study of Asthma that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 200 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02570984, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by Boston Children's Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
13
Study locations

Study Summary

This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.

Primary Outcome

questionnaire

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Omalizumab

Study Locations (13)

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • Rady Children's Hospital - San Diego - San Diego

Colorado

  • Childrens Hospital Colorado - Aurora

Connecticut

  • Connecticut Children's Hospital - Hartford

District of Columbia

  • Children's National Medical Center - Washington D.C.

Georgia

  • Emory University - Atlanta

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Indiana

  • Indiana University/Riley Children's Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2018-11-27
Est. Completion 2028-03-31
Phase Phase 2
Boston Children's Hospital

462 total trials

What the registry record for NCT02570984 still lists

NCT02570984 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02570984 lists 13 locations in 13 states (Arizona, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT02570984 about?

NCT02570984 is a clinical study titled "Preventing Asthma in High Risk Kids". This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction i...

What is the current status of trial NCT02570984?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2018-11-27. Estimated completion is 2028-03-31.

What conditions does trial NCT02570984 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT02570984?

The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG).

Who is sponsoring clinical trial NCT02570984?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02570984 being conducted?

This trial has 13 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02570984's enrollment target sits among peer trials

200 162nd of 374 higher than 210 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02570984, the US trial registry maintained by the National Library of Medicine. NCT02570984 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.